Atlas Trials

Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients

Clinical trial NCT04293887 · UNKNOWN

Trial details

NCT number
NCT04293887
Sponsor
Tongji Hospital
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
COVID-19Recombinant Human Interferon α1β
Start date
2020-03-01
Primary completion
2020-05-30
Enrollment
328

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.